All News
We are Doctors, Not Providers!
With apologies to Shakespeare, names are important. In health care, they can have ethical significance. The American College of Physicians has published a new ethics/position policy paper proclaiming that the term ‘provider’ should not be used to describe physicians, and using the blanket term undermines physicians’ ethical responsibility, clinical integrity, and professionalism.
Read Article
Staying Ahead of Spondyloarthritis
The diagnosis and treatment of spondyloarthritis can present challenging clinical scenarios for rheumatologists. At RheumNow Live, Pod IV focused on "Staying Ahead of Spondyloarthritis", which reviewed diagnosis, complications and advances in SpA.
Read Article
Advances in RA-ILD
Dr. Jeffrey Sparks gave a state of the art update on Advances in RA-ILD, many of which he and his group have played a big part in, on Saturday at RNL26.
Read Article
Study of 90 adolescents (46 w. Juvenile fibromyalgia (JFM) & 44 controls) finds that JFM pts have greater sensitivity to non-painful sensory stimuli, such as sounds and bright lights; such hypersensitivity is closely related to the severity of the disease and brain function https://t.co/KGqzRK6e4a
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/mJSmMakSBM
Dr. John Cush RheumNow ( View Tweet)
Rheum Cases & Guidelines
https://t.co/0zI2KRuwxa https://t.co/TBw12LFh6i
Dr. John Cush RheumNow ( View Tweet)
ANA Pollution (2.06.2026
Dr. Jack Cush reviews the news, journal articles, and regulatory news from this past week on RheumNow.
https://t.co/cfEjEr36Tb https://t.co/OJbE6P3k6p
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD
Mucosal Hypothesis RA #RNL26
Demoruelle
ACPA can predate RA development
Nam et al: non-specific jt pain: 42% developed RA in 12 mos
Circiumaro et al: MSK complaints 38% devel RA in 36 mo
APIPPRA: 29% at 12 mo, 37% at 24 mo, StopRA 18% in 12 mo, 33% at 36 mo https://t.co/JYiWmn0N0g
Dr. John Cush RheumNow ( View Tweet)
RT @richardPAconway
Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/TCsDfeQjZC
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinmd
Mortality risk in RA #RNL26
Myasoedova
Most common mortality:
1.5-1.6x increase risk CVD
2-3x increase risk ILD
+ACPA increases risk in both https://t.co/Luwyy6UFg6
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinmd
Mortality risk in RA #RNL26
Myasoedova
Premature deaths in up to 1/4 of pts
Decline in mortality in RA after year 2000
Full siblings of RA also high mortality (shared genetic or environ factors affect risk?)
Risks: Seropositivity, esp ACPA, CRP, extra-artic https://t.co/ytm6odmtgR
Dr. John Cush RheumNow ( View Tweet)
FDA vs. Amgen: At Odds Over Avacopan
The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market. https://t.co/v5AYm6r53W
Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Recent Government Funding
The American College of Rheumatology (ACR) praised the recent Congressional CY 26 funding package, highlighting its provisions to extend Medicare telehealth payment flexibilities, enhance transparency in pharmacy benefit management, and https://t.co/gr3X7RRGLN
Dr. John Cush RheumNow ( View Tweet)
SGLT2 Inhibitors in Gout - Better Outcomes, Fewer Meds
Natalie McCormick, PhD (RACER Center, Mass General Brigham), led a new Diabetes Care study on gout-related medication use after starting SGLT2 inhibitors in patients with gout and type 2 diabetes.
https://t.co/BFJB3OY2L3 https://t.co/63Bu4t6LYM
Links:
Dr. John Cush RheumNow ( View Tweet)
REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had to be ANA+ and 1-2 SLICC criteria at entry. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/s4Mzoec5ga
Dr. John Cush RheumNow ( View Tweet)
Factors that may augment future development of SLE - includes Vitamin D levels, poor sleep, EBV reactivation & social determinants of health. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/2J1JBjeXKU
Dr. John Cush RheumNow ( View Tweet)
Methotrexate intolerance in rheumatoid arthritis
A current large rheumatoid arthritis (RA) cohort study from Cairo assessed methotrexate (MTX) use and found over half were MTX intolerant and a third of patients were noncompliant with MTX.
https://t.co/ODiVqUXBb9 https://t.co/QwmNkrjvn6
Dr. John Cush RheumNow ( View Tweet)
Aortitis in Giant Cell Arteritis Treated with Tocilizumab
The Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group studied giant cell arteritis (GCA) with aortitis, comparing the efficacy of intravenous (IV) vs. subcutaneously (SC) tocilizumab (TCZ) - demonstrating https://t.co/yo7SDj5lgZ
Dr. John Cush RheumNow ( View Tweet)
DMARD Responses in Localized Scleroderma
JAMA Dermatology has published the results of a juvenile localized scleroderma (JLS) trial showing that mycophenolate mofetil (MMF) and methotrexate (MTX) are equally effective in treating JLS, noting low flare rates and possibly better https://t.co/6bDtVoCgRj
Dr. John Cush RheumNow ( View Tweet)
NEJM: Aortitis Due to Large-Vessel Vasculitis
63yoM w/ Hx HTN c/o 3 mos of CP, palpitations, abdominal pain. ESR-104, CRP 85 mg/L. CT showed thickening of the thoracic & abdominal aorta. After 6wks Rx w/ AZA, HCQ, Pred, ESR/CRP still high and pt stared on SC TCZ w/ improvement. https://t.co/1TBreptAFr
Dr. John Cush RheumNow ( View Tweet)
